Quanterix (NasdaqGM:QTRX) 2026 Conference Summary Company Overview - **Company**: Quanterix - **Industry**: Life Science Tools and Diagnostics - **Key Personnel**: Everett Cunningham (CEO), Vandana Sriram (CFO) Core Points and Arguments Business Position and Strategy - Quanterix is in the early stages of its growth journey, described as being in the "first inning" of its development [12] - The company has a solid balance sheet with $100 million in cash and no debt, aiming for cash flow break-even in the second half of the year [13] - The acquisition of Akoya has diversified Quanterix's focus from 90% neurology to 60% neurology and 40% oncology and immunology, enhancing its market position [18] Diagnostics Opportunity - Quanterix is focusing on diagnostics as a key growth driver, with a differentiated blood-based biomarker test currently under FDA review [14] - The company expects to receive feedback from the FDA on its 510(k) submission within 6 to 9 months [14] - Clinical utility studies are underway with three partners, with results expected in the second half of the year [14] Financial Performance - The fourth quarter performance exceeded expectations, driven by a strong recovery in consumables, which accounted for most of the sequential revenue increase [27] - The company reported that approximately 75% of its revenue is recurring, primarily from consumables [28] - For 2026, Quanterix is guiding a revenue growth of 0%-3%, reflecting a conservative approach due to market uncertainties [40] Competitive Landscape - Quanterix's diagnostic test has a 10% indeterminate zone, allowing 90% of patients to receive actionable results, which is a competitive advantage over others with higher indeterminate rates [55] - The company embraces competition as a means to improve its offerings and drive innovation [60] Accelerator Business - The Accelerator lab experienced a significant growth of 40% in 2024 but saw a decline in 2025 due to smaller project sizes [87] - The company aims to secure larger projects moving forward, leveraging existing relationships in the pharmaceutical industry [89] Operational Efficiency - Quanterix is targeting $85 million in operational expenses (OpEx) reduction, with a focus on maintaining a right-sized cost structure [93] - The company has achieved a gross margin of 50% and aims to improve profitability through volume growth [94] Future Outlook - The diagnostics plan will be solidified in the second half of the year, with a focus on early detection of Alzheimer's and other neurological conditions [37] - The company is prioritizing projects that align with its growth strategy, ensuring that resources are allocated effectively [96] Additional Important Insights - The company is actively engaging with key opinion leaders and payers to enhance its market position and ensure the successful rollout of its diagnostics [45] - Quanterix is committed to improving its product offerings based on customer feedback, particularly in the spatial and diagnostics segments [83] - The company recognizes the importance of maintaining a competitive edge in the rapidly evolving diagnostics market [84]

Quanterix FY Conference Summary Company Overview - **Company**: Quanterix (NasdaqGM: QTRX) - **Industry**: Life Sciences Tools and Diagnostics - **Key Management**: Everett Cunningham (CEO), Vandana Sriram (CFO) Core Points and Arguments Leadership Transition - Everett Cunningham, with over 30 years in healthcare, joined Quanterix from Illumina, attracted by the need for breakthrough technologies in neurology, oncology, and immunology [6][7] - Emphasized the solid base business in research tools and the potential for growth in diagnostics, particularly in Alzheimer's [7][8] Financial Health - Quanterix has a strong balance sheet with $100 million in cash and no debt [8] - The company aims to achieve breakeven cash flow in the second half of the year and has set a synergy target of $84 million from the Akoya acquisition by the end of Q1 [8] Growth Strategy - Projected growth for 2026 is between 0%-3%, with a focus on prioritizing next-generation platforms and technologies [14][16] - Plans to build a comprehensive diagnostics strategy, including reimbursement strategies and clinical utility studies, with results expected mid-year [18][19] Performance Insights - The fourth quarter showed a significant improvement, with consumables driving growth and a recurring revenue profile now at 75% [21][22] - The company is seeing a reduction in cash burn, down to approximately $3 million from previous levels of $15 million-$20 million [22] Akoya Acquisition - The acquisition has diversified Quanterix's business from 90% neurology to 60% neurology and 40% oncology/immunology, enhancing the company's market position [23][24] - Early integration efforts have been positive, with a unified company culture emerging [25][26] Market Position and Future Outlook - The company anticipates a return to high single-digit growth rates in a normalized market, driven by consumables and diagnostic partnerships [29][36] - The focus will be on optimizing technology and expanding the Accelerator Laboratory's role in generating insights for next-gen assay development [46][47] Alzheimer's Diagnostics - Quanterix is working on a multi-analyte blood test for Alzheimer's, with a 510(k) submission made in January and results expected in 6-9 months [66][73] - The company aims to establish an end-to-end strategy for diagnostics, leveraging its CLIA lab capabilities [95][96] Competitive Landscape - Quanterix's LucentAD test is positioned as a unique offering with high sensitivity and specificity, differentiating it from competitors [103][104] - The company welcomes competition as it indicates market attractiveness and is committed to maintaining a strong commercial approach [121][123] Additional Important Insights - The Accelerator Laboratory serves as a leading indicator for customer interests and next-gen assay development [46][47] - The company is expanding its infrastructure outside the U.S., particularly in markets with aging populations like China and Korea [116] - Future growth opportunities are anticipated from service offerings similar to those in the Accelerator Laboratory [65] This summary encapsulates the key points discussed during the Quanterix FY Conference, highlighting the company's strategic direction, financial health, and market positioning within the life sciences tools and diagnostics industry.

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

分组1 - Quanterix Corporation reported a quarterly loss of $0.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.27, and compared to a loss of $0.30 per share a year ago, indicating an earnings surprise of -40.74% [1] - The company posted revenues of $43.86 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 14.71%, and showing an increase from $35.16 million in the same quarter last year [2] - Quanterix shares have increased by approximately 3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $38.58 million, and for the current fiscal year, it is -$0.85 on revenues of $173.87 million [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 43% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $43.9 million, a 25% increase year-over-year and a 7% increase sequentially [11] - Organic revenue declined by 22% [11] - Adjusted EBITDA was a loss of $7.9 million, an improvement from a loss of $11.9 million in Q3 [16] - The company ended the quarter with $122 million in cash equivalents and marketable securities [16] Business Line Data and Key Metrics Changes - Revenue from diagnostics partners was $3.1 million in the quarter [11] - Simoa contributed $27 million, reflecting a 22% organic revenue decline [11] - Spatial reported $17 million, down 23% year-over-year, with a 16% decline when excluding a terminated diagnostics development agreement [11] - Instrument revenue was $6.1 million, with 21 Simoa and 17 Spatial instruments placed in the quarter [12] Market Data and Key Metrics Changes - Academic customers represented approximately 55% of the business in Q4 [12] - Pharma revenue declined by 21% year-over-year due to lower large Accelerator projects [13] - The company has 25 partnerships generating $9.6 million in revenue during 2025, up from $6 million in the prior year [13] Company Strategy and Development Direction - The company aims to achieve break-even profitability in 2026, with a focus on operational rigor and steady growth [8][16] - The LucentAD Complete test for Alzheimer's disease has received a reimbursement rate approval of $897, which is expected to enhance market penetration [14] - The company plans to launch additional products in the tau biomarker field, indicating a commitment to innovation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's base business and the plan for break-even profitability [19] - The CEO emphasized the importance of understanding customer needs and strategic partnerships to drive growth [9] - The company anticipates a minimal impact on core business from the terminated diagnostics agreement, with pro forma revenue expected to increase by approximately 2% in 2026 [18] Other Important Information - The company has implemented $74 million of its $85 million cost synergy target and is on track to meet this by the end of Q1 [16] - The company launched 13 new assays in 2025 and plans for a continuous stream of assay launches throughout 2026 [27] Q&A Session Summary Question: Assessment of Quanterix's core high sensitivity proteomics and Spatial Biology businesses - The CEO noted effective execution in diversifying the business and achieving synergy targets, with a focus on growth in both Simoa and Akoya spatial spaces [23][24] Question: New assay or product launches planned for 2026 - The CFO confirmed a regular cadence of assay launches is expected, with several already in the pipeline for Q1 [27] Question: Prioritization of diagnostics versus Simoa proteomics and Spatial business - The CEO highlighted the importance of the Alzheimer's diagnostics opportunity and ongoing clinical utility studies to guide payer engagement [34] Question: Update on FDA submission and potential timeline for product approval - The CEO mentioned that the FDA approval for the 510(k) submission is expected within 6 to 9 months, aiming for Q4 approval [38]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $43.9 million, representing a 25% increase year-over-year and a 7% sequential increase [11] - Organic revenue declined by 22% [11] - Adjusted EBITDA loss was $7.9 million, an improvement of $4 million from a loss of $11.9 million in Q3 [16] - Cash equivalents, marketable securities, and restricted cash at the end of the quarter totaled $122 million [16] Business Line Data and Key Metrics Changes - Simoa contributed $27 million, reflecting a 22% organic revenue decline [11] - Spatial reported $17 million, down 23% year-over-year, with a 16% decline when excluding a terminated diagnostics development agreement [11] - Instrument revenue was $6.1 million, with 21 Simoa and 17 Spatial instruments placed in the quarter [12] - Consumables revenue was $23 million, up $3.8 million sequentially [12] Market Data and Key Metrics Changes - Academic customers represented approximately 55% of the business in Q4 [12] - Pharma revenue declined by 21% year-over-year due to lower large Accelerator projects [13] - Diagnostics partnerships generated $9.6 million in revenue during 2025, up from $6 million in the prior year [13] Company Strategy and Development Direction - The company aims to achieve break-even profitability in 2026, with a focus on operational rigor and steady growth [8][16] - The strategy includes expanding the diagnostics market, particularly in Alzheimer's disease, leveraging its ultrasensitive platforms [8] - The company has completed major integration activities and is focusing on profitable growth [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the base business and the plan for break-even profitability [19] - The company is focused on generating clinical utility data for the LucentAD Complete test to support payer conversations [14][34] - The FDA submission for the LucentAD test is expected to take 6 to 9 months, with anticipated approval by Q4 2026 [38] Other Important Information - The company launched 13 new assays in 2025 and plans for a continuous stream of assay launches throughout 2026 [27] - The terminated diagnostics development agreement had a minimal impact on the core business for 2026 [18] Q&A Session Summary Question: Assessment of Quanterix's core high sensitivity proteomics and Spatial Biology businesses - Management is assessing the diversified strategy and is pleased with the increased diversification in the Spatial business post-Akoya acquisition [23][24] Question: New assay or product launches planned for 2026 - The company expects a regular cadence of assay launches every quarter, with several already in the pipeline for Q1 [27] Question: Prioritization of diagnostics versus Simoa proteomics versus Spatial business - Management is excited about the diagnostics opportunity, particularly in Alzheimer's, and is focusing on payer engagement and reimbursement strategies [34] Question: Update on FDA submission and potential timeline - The FDA approval for the LucentAD test is expected within 6 to 9 months, with a focus on establishing a good payer strategy [38]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $43.9 million, a 25% increase year-over-year and a 7% increase sequentially [11] - Organic revenue declined by 22% [11] - Adjusted EBITDA was a loss of $7.9 million, an improvement from a loss of $11.9 million in Q3 [16] - The company ended the quarter with $122 million in cash equivalents and marketable securities [16] Business Line Data and Key Metrics Changes - Revenue from diagnostics partners was $3.1 million in the quarter [11] - Simoa contributed $27 million, reflecting a 22% organic revenue decline [11] - Spatial reported $17 million, down 23% year-over-year, with a 16% decline when excluding a terminated diagnostics development agreement [11] - Instrument revenue was $6.1 million, with 21 Simoa and 17 Spatial instruments placed in the quarter [12] Market Data and Key Metrics Changes - Academic customers represented approximately 55% of the business in Q4 [12] - Pharma revenue declined by 21% year-over-year due to lower large Accelerator projects [13] - The company has 25 partnerships generating $9.6 million in revenue during 2025, up from $6 million in the prior year [13] Company Strategy and Development Direction - The company aims for break-even profitability in 2026, with a focus on operational rigor and steady growth [8][16] - The management is prioritizing the diagnostics market, particularly in Alzheimer's disease, leveraging its ultrasensitive platforms [8] - The company plans to continue launching new assays and expanding its product offerings [14][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving break-even profitability and scaling the business into profitable growth areas [19] - The company is focused on generating clinical utility data for its LucentAD Complete test to support payer conversations [14][36] - The management anticipates a minimal impact from the terminated diagnostics development agreement on core business in 2026 [18] Other Important Information - The company has implemented $74 million of its $85 million cost synergy target and is on track to meet this by the end of Q1 [16] - The company launched 13 new assays in 2025 and plans for a continuous stream of assay launches throughout 2026 [28] Q&A Session Summary Question: Assessment of Quanterix's core high sensitivity proteomics and Spatial Biology businesses - Management highlighted effective execution in diversifying the business and achieving synergy targets, with a focus on growth in both Simoa and Akoya spatial spaces [24][25] Question: New assay or product launches planned for 2026 - Management confirmed a continuous stream of assay launches is expected throughout 2026, with several already in the pipeline for Q1 [28] Question: Prioritization of diagnostics versus Simoa proteomics and Spatial business - Management emphasized the importance of the Alzheimer's diagnostics opportunity and ongoing clinical utility studies to guide payer engagement [35][36] Question: Update on FDA submission and potential timeline for approval - Management expects FDA approval for the 510(k) submission within 6 to 9 months, anticipating approval by Q4 [40]

Financial Performance - Total revenues for Quanterix Corporation were $138.9 million in 2025, a slight increase from $137.4 million in 2024[312]. - The company incurred net losses of $107.2 million in 2025, compared to $38.5 million in 2024, indicating a significant increase in losses[312]. - Total revenues increased by $1.5 million, or 1%, to $138.9 million for the year ended December 31, 2025, compared to $137.4 million for 2024[343]. - Product revenue rose by $13.2 million, or 17%, to $92.9 million, primarily due to the acquisition of Akoya, which contributed $21.9 million[344]. - Service and other revenue decreased by $7.0 million, or 14%, to $44.2 million, largely due to a $18.8 million decline in the legacy Quanterix business[345]. - Gross profit decreased by $18.1 million, or 22%, to $64.9 million, with gross margin dropping from 60% to 47%[342]. - Selling, general and administrative expenses increased by $36.4 million, or 36%, to $138.0 million, influenced by the acquisition of Akoya[352]. - Research and development expenses rose by $4.8 million, or 16%, to $35.9 million, driven by the acquisition of Akoya[351]. - The adjusted loss from operations for Q4 2025 was $15,004 thousand, compared to a loss of $13,669 thousand in Q4 2024[405]. Cash Flow and Liquidity - As of December 31, 2025, the company had $29.8 million in cash and cash equivalents and $88.4 million in marketable securities, indicating sufficient liquidity for at least 12 months[358]. - Net cash used in operating activities increased to $77.2 million in 2025 from $35.2 million in 2024, primarily due to a rise in net loss and inclusion of Akoya's operating results[365]. - Cash used in operations included payments for professional fees related to the acquisition of Akoya, contributing to the overall increase in cash outflow[365]. - Net cash provided by investing activities was $50.2 million in 2025, reflecting $93.2 million used for acquisitions and $69.8 million for marketable securities purchases, offset by $215.8 million from maturities of marketable securities[367]. - The company experienced negative cash flows historically due to investments in technology and infrastructure development[364]. Acquisitions and Impairments - The acquisition of Akoya was completed for a total consideration of $151.0 million, which included $49.9 million in common stock and $101.1 million in cash[315]. - The company recorded a goodwill impairment charge of $6.4 million in Q2 2025 due to a decline in revenue and bookings[323]. - Impairment and restructuring costs amounted to $15.7 million for the year ended December 31, 2025, with no such costs recorded in 2024[355]. - Impairment charges for goodwill and acquired leased facilities not in use amounted to $17,531 thousand for the year ended December 31, 2025[407]. - The acquisition of Emission includes a potential earnout of up to $50.0 million based on performance targets, with a fair value of $2.0 million recorded as of December 31, 2025[371]. Future Outlook - Quanterix expects to achieve cash flow breakeven in 2026, contingent on meeting revenue and expense objectives following the acquisition of Akoya Biosciences[313]. - Restructuring actions in 2025 are expected to reduce annualized operating expenses by approximately $74.0 million, with a goal of $85.0 million by 2026[324]. - The company expects to achieve cash flow breakeven by 2026, contingent on meeting revenue and expense objectives[364]. Market and Regulatory Developments - The Centers for Medicare & Medicaid Services approved a reimbursement rate of $897 for the LucentAD Complete multiplex test in November 2025, enhancing access to the diagnostic solution[322]. - Quanterix submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test for Alzheimer's disease on January 31, 2026[320]. - Approximately 40% of total revenue in 2025 was generated from international customers, up from 37% in 2024, indicating increased exposure to foreign currency exchange risks[410]. - A hypothetical 10% adverse change in foreign exchange rates would decrease potential cash inflows from foreign denominated receivables by $0.6 million[410]. - The company has not entered into any foreign currency hedging contracts to date but may consider doing so in the future[411]. Revenue Recognition - The company recognizes revenue from contracts with customers based on a five-step framework, ensuring compliance with ASC 606[377].

Legal Information Fourth Quarter & Full Year 2025 Earnings Presentation March 2, 2026 1 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this presentation that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looki ...

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the goals of both ...